922 related articles for article (PubMed ID: 30002098)
1. Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.
Haynes R; Judge PK; Staplin N; Herrington WG; Storey BC; Bethel A; Bowman L; Brunskill N; Cockwell P; Hill M; Kalra PA; McMurray JJV; Taal M; Wheeler DC; Landray MJ; Baigent C
Circulation; 2018 Oct; 138(15):1505-1514. PubMed ID: 30002098
[TBL] [Abstract][Full Text] [Related]
2. Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data.
UK HARP-III Collaborative Group
Nephrol Dial Transplant; 2017 Dec; 32(12):2043-2051. PubMed ID: 27646835
[TBL] [Abstract][Full Text] [Related]
3. Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: A meta-analysis.
Kang H; Zhang J; Zhang X; Qin G; Wang K; Deng Z; Fang Y; Chen G
Eur J Pharmacol; 2020 Oct; 884():173444. PubMed ID: 32739172
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.
Kang DH; Park SJ; Shin SH; Hong GR; Lee S; Kim MS; Yun SC; Song JM; Park SW; Kim JJ
Circulation; 2019 Mar; 139(11):1354-1365. PubMed ID: 30586756
[TBL] [Abstract][Full Text] [Related]
5. Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease.
Lee WC; Liao TW; Chen TY; Fang HY; Fang YN; Chen HC; Lin YS; Chang SH; Chen MC
Cardiovasc Drugs Ther; 2024 Jun; 38(3):505-515. PubMed ID: 36609948
[TBL] [Abstract][Full Text] [Related]
6. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.
Damman K; Gori M; Claggett B; Jhund PS; Senni M; Lefkowitz MP; Prescott MF; Shi VC; Rouleau JL; Swedberg K; Zile MR; Packer M; Desai AS; Solomon SD; McMurray JJV
JACC Heart Fail; 2018 Jun; 6(6):489-498. PubMed ID: 29655829
[TBL] [Abstract][Full Text] [Related]
7. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
8. Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study.
Ganesananthan S; Shah N; Shah P; Elsayed H; Phillips J; Parkes A; Morgan A; Yousef Z
Open Heart; 2020 Oct; 7(2):. PubMed ID: 33020255
[TBL] [Abstract][Full Text] [Related]
9. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
[TBL] [Abstract][Full Text] [Related]
10. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.
Martens P; Beliën H; Dupont M; Vandervoort P; Mullens W
Cardiovasc Ther; 2018 Aug; 36(4):e12435. PubMed ID: 29771478
[TBL] [Abstract][Full Text] [Related]
11. "Real World" Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry.
Simpson J; Benson L; Jhund PS; Dahlström U; McMurray JJV; Lund LH
Cardiovasc Drugs Ther; 2019 Jun; 33(3):315-322. PubMed ID: 30903545
[TBL] [Abstract][Full Text] [Related]
12. Sacubitril/Valsartan in Real-Life Practice: Experience in Patients with Advanced Heart Failure and Systematic Review.
Moliner-Abós C; Rivas-Lasarte M; Pamies Besora J; Fluvià-Brugues P; Solé-González E; Mirabet S; López López L; Brossa V; Pirla MJ; Mesado N; Álvarez-García J; Roig E
Cardiovasc Drugs Ther; 2019 Jun; 33(3):307-314. PubMed ID: 30820802
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial.
DeVore AD; Mi X; Thomas L; Sharma PP; Albert NM; Butler J; Hernandez AF; Patterson JH; Spertus JA; Williams FB; Duffy CI; McCague K; Fonarow GC
J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29895587
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
Mohanty AF; Levitan EB; Dodson JA; Vardeny O; King JB; LaFleur J; He T; Patterson OV; Alba PR; Russo PA; Choi ME; Bress AP
Circ Heart Fail; 2019 Nov; 12(11):e005691. PubMed ID: 31718321
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction.
Mc Causland FR; Lefkowitz MP; Claggett B; Anavekar NS; Senni M; Gori M; Jhund PS; McGrath MM; Packer M; Shi V; Van Veldhuisen DJ; Zannad F; Comin-Colet J; Pfeffer MA; McMurray JJV; Solomon SD
Circulation; 2020 Sep; 142(13):1236-1245. PubMed ID: 32845715
[TBL] [Abstract][Full Text] [Related]
16. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
Greene SJ; Choi S; Lippmann SJ; Mentz RJ; Greiner MA; Hardy NC; Hammill BG; Luo N; Samsky MD; Heidenreich PA; Laskey WK; Yancy CW; Peterson PN; Curtis LH; Hernandez AF; Fonarow GC; O'Brien EC
J Am Heart Assoc; 2021 Aug; 10(16):e021459. PubMed ID: 34350772
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of the Combination of Sacubitril/Valsartan and SGLT2i in HFrEF Patients (SECSI Registry).
Jiménez-Blanco Bravo M; Valle A; Gayán Ordás J; Del Prado Díaz S; Cordero Pereda D; Morillas Climent H; Bascompte Claret R; Seller Moya J; Zamorano Gómez JL; Alonso Salinas GL
J Cardiovasc Pharmacol; 2021 Nov; 78(5):e662-e668. PubMed ID: 34321396
[TBL] [Abstract][Full Text] [Related]
18. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial.
Desai AS; Solomon S; Claggett B; McMurray JJ; Rouleau J; Swedberg K; Zile M; Lefkowitz M; Shi V; Packer M
Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27296397
[TBL] [Abstract][Full Text] [Related]
19. Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction.
Fudim M; Sayeed S; Xu H; Matsouaka RA; Heidenreich PA; Velazquez EJ; Yancy CW; Fonarow GC; Hernandez AF; DeVore AD
Circ Heart Fail; 2020 Apr; 13(4):e006645. PubMed ID: 32248695
[TBL] [Abstract][Full Text] [Related]
20. Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure.
Chatur S; Neuen BL; Claggett BL; Beldhuis IE; Mc Causland FR; Desai AS; Rouleau JL; Zile MR; Lefkowitz MP; Packer M; McMurray JJV; Solomon SD; Vaduganathan M
J Am Coll Cardiol; 2024 Jun; 83(22):2148-2159. PubMed ID: 38588927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
